Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Lucas F, Larkin K, Gregory CT, Orwick S, Doong TJ, Lozanski A, Lozanski G, Misra S, Ngankeu A, Ozer HG, Sampath D, Thangavadivel S, Yilmaz SA, Rogers KA, Byrd JC, Woyach JA, Blachly JS. Lucas F, et al. Among authors: lozanski a. Blood. 2020 Jun 11;135(24):2192-2195. doi: 10.1182/blood.2019003722. Blood. 2020. PMID: 32232486 Free PMC article. No abstract available.
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones J, Flynn J, Maddocks K, O'Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JC. Woyach JA, et al. Among authors: lozanski a, lozanski g. Blood. 2014 Mar 20;123(12):1810-7. doi: 10.1182/blood-2013-09-527853. Epub 2014 Jan 10. Blood. 2014. PMID: 24415539 Free PMC article.
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC, Dubovsky JA, Johnson AJ. Liu TM, et al. Among authors: lozanski a, lozanski g. Blood. 2015 Jul 2;126(1):61-8. doi: 10.1182/blood-2015-02-626846. Epub 2015 May 13. Blood. 2015. PMID: 25972157 Free PMC article.
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC. Woyach JA, et al. Among authors: lozanski a, lozanski g. N Engl J Med. 2014 Jun 12;370(24):2286-94. doi: 10.1056/NEJMoa1400029. Epub 2014 May 28. N Engl J Med. 2014. PMID: 24869598 Free PMC article.
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Maddocks KJ, et al. Among authors: lozanski a. JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218. JAMA Oncol. 2015. PMID: 26182309 Free PMC article.
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.
Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo L, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong TJ, Ny F, Lucas M, Chase W, Jones JA, Flynn JM, Maddocks K, Rogers K, Jaglowski S, Andritsos LA, Awan FT, Blum KA, Grever MR, Lozanski G, Johnson AJ, Byrd JC. Woyach JA, et al. Among authors: lozanski a. J Clin Oncol. 2017 May 1;35(13):1437-1443. doi: 10.1200/JCO.2016.70.2282. Epub 2017 Feb 13. J Clin Oncol. 2017. PMID: 28418267 Free PMC article. Clinical Trial.
LC-FACSeq is a method for detecting rare clones in leukemia.
Hu EY, Blachly JS, Saygin C, Ozer HG, Workman SE, Lozanski A, Doong TJ, Chiang CL, Bhat S, Rogers KA, Woyach JA, Coombes KR, Jones D, Muthusamy N, Lozanski G, Byrd JC. Hu EY, et al. Among authors: lozanski a. JCI Insight. 2020 Jun 18;5(12):e134973. doi: 10.1172/jci.insight.134973. JCI Insight. 2020. PMID: 32554930 Free PMC article.
Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivity.
Chiang CL, Hu EY, Chang L, Labanowska J, Zapolnik K, Mo X, Shi J, Doong TJ, Lozanski A, Yan PS, Bundschuh R, Walker LA, Gallego-Perez D, Lu W, Long M, Kim S, Heerema NA, Lozanski G, Woyach JA, Byrd JC, Lee LJ, Muthusamy N. Chiang CL, et al. Among authors: lozanski a. Cell Rep. 2022 Jul 19;40(3):111115. doi: 10.1016/j.celrep.2022.111115. Cell Rep. 2022. PMID: 35858552 Free article.
Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq.
Saygin C, Hu E, Zhang P, Sher S, Lozanski A, Doong TJ, Nicolet D, Orwick S, Labanowska J, Skinner JN, Cempre C, Kauffman T, Goettl VM, Heerema NA, Abruzzo L, Miller C, Lapalombella R, Behbehani G, Mims AS, Larkin K, Grieselhuber N, Walker A, Bhatnagar B, Bloomfield CD, Byrd JC, Lozanski G, Blachly JS. Saygin C, et al. Among authors: lozanski a. Leukemia. 2021 Dec;35(12):3406-3420. doi: 10.1038/s41375-021-01295-1. Epub 2021 May 21. Leukemia. 2021. PMID: 34021247 Free PMC article.
Clonal hematopoiesis of indeterminate potential in the companion dog.
Sebastian K, Özer HG, Howard C, Chadsey L, Lozanski A, Doong TJ, Orwick S, Lozanski G, Ma W, Kisseberth WC, Byrd JC, Harrington BK. Sebastian K, et al. Among authors: lozanski a. Leukemia. 2022 May;36(5):1401-1403. doi: 10.1038/s41375-022-01520-5. Epub 2022 Feb 10. Leukemia. 2022. PMID: 35145204 No abstract available.
19 results